Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | DNA topoisomerase I | 0.405754 | 1 | 1 |
Echinococcus multilocularis | DNA topoisomerase 1 | 0.405754 | 1 | 1 |
Echinococcus granulosus | DNA topoisomerase 1 | 0.405754 | 1 | 1 |
Schistosoma mansoni | DNA topoisomerase type I | 0.405754 | 1 | 1 |
Schistosoma mansoni | DNA topoisomerase type I | 0.299126 | 0.735311 | 0.735311 |
Toxoplasma gondii | DNA topoisomerase I, putative | 0.405754 | 1 | 1 |
Brugia malayi | DNA topoisomerase I | 0.405754 | 1 | 1 |
Brugia malayi | Protein kinase domain containing protein | 0.0220261 | 0.0474506 | 0.0474506 |
Schistosoma mansoni | DNA topoisomerase type I | 0.299126 | 0.735311 | 0.735311 |
Trichomonas vaginalis | prokaryotic DNA topoisomerase, putative | 0.002911 | 0 | 0.5 |
Plasmodium vivax | topoisomerase I, putative | 0.405754 | 1 | 1 |
Trypanosoma brucei | DNA topoisomerase IB, large subunit | 0.299126 | 0.735311 | 1 |
Mycobacterium leprae | Probable DNA topoisomerase I TopA (omega-protein) (relaxing enzyme) (untwisting enzyme) (swivelase) (type I DNA topoisomerase) ( | 0.002911 | 0 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | topoisomerase IA, TopA | 0.002911 | 0 | 0.5 |
Trypanosoma cruzi | DNA topoisomerase type IB small subunit, putative | 0.198187 | 0.484744 | 0.659237 |
Leishmania major | DNA topoisomerase IB, large subunit | 0.299126 | 0.735311 | 1 |
Trypanosoma brucei | DNA topoisomerase type IB small subunit | 0.198187 | 0.484744 | 0.659237 |
Chlamydia trachomatis | DNA topoisomerase I | 0.002911 | 0 | 0.5 |
Leishmania major | DNA topoisomerase type IB small subunit | 0.198187 | 0.484744 | 0.659237 |
Plasmodium falciparum | topoisomerase I | 0.405754 | 1 | 1 |
Schistosoma mansoni | neuropeptide receptor | 0.0136745 | 0.0267189 | 0.0267189 |
Trichomonas vaginalis | prokaryotic DNA topoisomerase, putative | 0.002911 | 0 | 0.5 |
Giardia lamblia | DNA topoisomerase III | 0.002911 | 0 | 0.5 |
Loa Loa (eye worm) | CAMK/CAMKL/CHK1 protein kinase | 0.0220261 | 0.0474506 | 0.0474506 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0220261 | 0.0474506 | 0.0474506 |
Echinococcus multilocularis | neuropeptide receptor | 0.0136745 | 0.0267189 | 0.0267189 |
Echinococcus multilocularis | 0.0502161 | 0.117428 | 0.117428 | |
Mycobacterium ulcerans | DNA topoisomerase I | 0.002911 | 0 | 0.5 |
Echinococcus granulosus | neuropeptide receptor | 0.0136745 | 0.0267189 | 0.0267189 |
Treponema pallidum | DNA topoisomerase I (topA) | 0.002911 | 0 | 0.5 |
Entamoeba histolytica | DNA topoisomerase III, putative | 0.002911 | 0 | 0.5 |
Trypanosoma cruzi | DNA topoisomerase IB, large subunit, putative | 0.299126 | 0.735311 | 1 |
Echinococcus multilocularis | G protein coupled receptor 139 | 0.0136745 | 0.0267189 | 0.0267189 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
CC50 (ADMET) | = 16 uM | Cytotoxicity against human MRC5 cells after 7 days by MTT assay | ChEMBL. | 18226428 |
IC50 (functional) | Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum K1/Thailand by [3H]hypoxanthine uptake | ChEMBL. | 18226428 | |
IC50 (functional) | Antimalarial activity against chloroquine-sensitive Plasmodium falciparum THAI/Thailand as [3H]hypoxanthine uptake after 24 hrs by semi-automated micro dilution | ChEMBL. | 18226428 | |
IC50 (functional) | = 18.8 nM | Antimalarial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum FcB1R/Colombia by [3H]hypoxanthine uptake | ChEMBL. | 18226428 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18226428 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.